COLARIS AP ®: Genetic Testing for Adenomatous Polyposis Colon Cancer Syndromes
COLARIS AP ® detects mutations in the APC and MYH genes, which cause adenomatous polyposis colon cancer syndromes, including familial adenomatous polyposis (FAP), attenuated FAP (AFAP) and MYH -associated polyposis (MAP). The most common adenomatous polyposis conditions are thought to account for approximately two percent of all colon cancer.
COLARIS AP ® uses a simple blood or oral rinse sample to determine if patients have an APC or MYH mutation. Knowing the results may help patients and their healthcare providers act before cancer has a chance to develop.
Myriad has developed a Hereditary Cancer Quiz that patients and their healthcare providers can use to help identify potential candidates for genetic testing with COLARIS AP ®.
Benefits of COLARIS AP ® Testing
The results of the COLARIS AP ® test enable patients and their healthcare professionals to develop an individualized medical management plan to significantly reduce the risk of cancer. COLARIS AP ® helps healthcare professionals to:
- Personalize patient care and increase clinical efficiency by targeting increased surveillance and other interventions specifically to individuals with APC or MYH gene mutation(s);
- Improve patient compliance with tailored screening recommendations and preventive measures;
- Significantly improve outcomes and reduce medical costs through early diagnosis and treatment of cancer;
- Counsel patients and their family members on the underlying cause of the cancer or adenomas;
- Avoid unnecessary interventions involving family members who do not test positive for the mutation(s) known to be in the family; and
- Differentiate between AFAP, MAP and Lynch syndrome.
Medical Management and COLARIS AP ®
If a COLARIS AP ® test result confirms the presence of adenomatous polyposis syndromes, the following medical management options may help reduce or even eliminate the risk of cancer.
Attenuated FAP (AFAP):
- Increased surveillance
- Surgical management
MYH -Associated Polyposis (MAP):
- For patients who have MAP, medical society management recommendations include colonoscopies every one to two years starting at age 25-30, upper endoscopies every three to five years starting at age 30-35, and surgical options. The most appropriate medical management will vary based upon the patient’s clinical presentation.
- For MYH mutation carriers (one mutation), medical management should be determined by clinical findings and a personal and family history of colorectal polyps and/or cancer. Current data are limited but suggest that any increase in risk, if present, is likely to be small.
Familial Adenomatous Polyposis (FAP):
- Increased surveillance
- Chemoprevention
- Surgical management
For more healthcare professional information please visit MyriadPro.com.